1ère étape franchie - ACHAT - OC 14€ (vs 12€)
Alors que nous anticipions une approbation au T3/T4 de cette année, la FDA a donné hier son feu vert pour Zerviate (AC-170) dans le traitement des prurits oculaires associés aux conjonctivites allergiques. Nous considérons cette approbation comme une excellente nouvelle pour le groupe car elle devrait laisser du temps à NICOX pour trouver un partenaire commercial en amont de la période des allergies (printemps 2018). Nous maintenons notre recommandation ACHAT avec un OC relevé à 14€ (vs 12€). Prochain catalyseur: l’approbation de Vyzulta (24 août).Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.